Program
mesutoclax
Also written as “ICP-248”, “ICP-248+Orelabrutinib” and “Mesutoclax (ICP-248)”.
Its studies are mostly in Leukemia, Myeloid, Acute · Lymphoma, Mantle-Cell · Hematologic Neoplasms · Lymphoma, B-Cell, Marginal Zone, led by InnoCare Pharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| InnoCare Pharma | 88 open or running | phase 3since Apr 6, 2024 | Jan 12, 2023 | Jun 2027phase 1 · NCT06656494 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 12, 2023First study: phase 1 study in Hematologic NeoplasmsFirst studyNCT05728658 · 191 planned · China
- Apr 2, 2024Phase 1 study in Mature B-cell MalignanciesNCT06351527 · 78 planned · United States, Puerto Rico, Ukraine
- Apr 6, 2024Phase 3 study in Hematologic NeoplasmsNCT06378138 · 226 planned · China
- Oct 21, 2024Phase 1 study in Leukemia, Myeloid, AcuteNCT06656494 · 266 planned · United States, Australia, China
- Jul 15, 2025Phase 2 study in RecurrenceNCT07082686 · 75 planned · China
- Aug 17, 2026Phase 3 study in RecurrenceNCT07784101 · 280 planned · China
- Oct 19, 20262 phase 3 studiesNCT07896590, NCT07925190
Ahead
- Jun 2027Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT06656494
- Jun 25, 2027Primary completion: phase 1 study in Mature B-cell MalignanciesNCT06351527
- Dec 2027Primary completion: phase 2 study in RecurrenceNCT07082686
- Oct 2028Primary completion: phase 3 study in Lymphoma, B-Cell, Marginal ZoneNCT07896590
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07925190Leukemia, Myeloid, Acute · China | 3 | Recruiting | Dec 2029 | 318 |
| NCT07896590Lymphoma, B-Cell, Marginal Zone · China | 3 | Not yet recruiting | Oct 2028 | 292 |
| NCT07784101Recurrence · China | 3 | Not yet recruiting | Oct 2032 | 280 |
| NCT07082686Recurrence · China | 2 | Recruiting | Dec 2027 | 75 |
| NCT06656494Leukemia, Myeloid, Acute · United States, Australia, China | 1 | Recruiting | Jun 2027 | 266 |
| NCT06378138Hematologic Neoplasms · China | 3 | Recruiting | Nov 25, 2030 | 226 |
| NCT06351527Mature B-cell Malignancies · United States, Puerto Rico, Ukraine | 1 | Recruiting | Jun 25, 2027 | 78 |
| NCT05728658Hematologic Neoplasms · China | 1 | Recruiting | Aug 30, 2025 | 191 |
How it is read
Names in the registry
- “ICP-248”, 8 entries
- “ICP-248+Orelabrutinib”, 3 entries
- “Mesutoclax (ICP-248)”, 1 entry
- “ICP-248 +Rituximab”, 1 entry
- “ICP-248+Orelabrutinib+Rituximab”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 2 studies
- Lymphoma, Mantle-Cell, 2 studies
- Hematologic Neoplasms, 2 studies
- Lymphoma, B-Cell, Marginal Zone, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.